Altered gut microbiota profile in patients with generalized anxiety disorderOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study performed a systematic comparative analysis of the gut microbiome in people with generalized anxiety disorder (GAD) versus healthy controls. Researchers examined microbial richness, diversity, and taxonomic composition using metagenomic profiling. They also tested whether an antidepressant-naive subgroup showed the same pattern, and whether microbial changes reversed once anxiety went into remission.
Who was studied?
The primary cross-sectional cohort included 40 patients with GAD in an active anxious state and 36 healthy controls. A validation subgroup analysis was performed in 12 antidepressant-naive patients and 22 controls. A prospective subgroup of nine GAD patients was followed longitudinally, comparing their microbiome during active anxiety and again after remission.
What were the most important findings?
Patients with GAD had markedly decreased microbial richness and diversity compared with healthy controls, along with a distinct metagenomic composition. Short-chain fatty acid (SCFA)-producing bacteria, which are associated with a healthy gut status, were reduced in GAD patients. There was overgrowth of Escherichia-Shigella, Fusobacterium, and Ruminococcus gnavus. Unexpectedly, these genus-level changes did not reverse when patients achieved remission from anxiety.
What are the greatest implications of this study?
The findings identify a distinct gut microbiota dysbiosis signature associated with GAD, marked by loss of SCFA producers and overgrowth of specific pathobionts. The persistence of dysbiosis into remission suggests the microbiome alteration is not simply a transient marker of active anxiety symptoms. This raises the possibility that the microbiome itself could be a therapeutic and preventive target for GAD, rather than only a downstream consequence of the disorder.